H.I.G. Capital’s Strategic Expansion into Healthcare and Beyond
In recent developments, H.I.G. Capital, a prominent global alternative investment firm, continues to strengthen its presence in the healthcare sector and beyond. With $65 billion in capital under management, H.I.G. Capital has been making strategic moves that highlight its commitment to innovation and growth.
One of the key acquisitions for H.I.G. Capital is SkinCure Oncology, a leader in image-guided superficial radiation therapy for nonmelanoma skin cancer. This acquisition underscores H.I.G. Capital’s dedication to advancing non-invasive cancer treatment solutions, positioning itself at the forefront of healthcare technology.
Meanwhile, H.I.G. Capital also concluded the sale of BIOVECTRA, a contract development and manufacturing organization. This sale to Agilent Technologies, valued at $925 million, marks a significant milestone. Under H.I.G. Capital’s guidance, BIOVECTRA saw substantial growth, demonstrating the firm’s ability to enhance the value and performance of its portfolio companies.
Moreover, H.I.G. Capital expanded its reach into the organic market by acquiring a majority stake in Naturalia Tantum S.p.A., an Italian leader in organic personal care products. This move reflects the firm’s strategic interest in the burgeoning natural products market, aiming to cater to an increasingly eco-conscious consumer base.
Beyond direct healthcare investments, H.I.G. Capital ventured into support services by acquiring Action Elevator. This acquisition broadens its footprint in the healthcare infrastructure market, providing essential maintenance and modernization services.
These strategic actions by H.I.G. Capital illustrate its multi-faceted approach to investment, focusing on sectors with robust growth potential. With a keen eye on future trends, H.I.G. Capital continues to shape its portfolio, paving the way for advancements in both healthcare and related industries.